Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q1 2025 Earnings Presentation
13 slides from Bionano Genomics's earnings presentation, May 14, 2025
Slide 1: Q1'25 Financial Results Webcast & Call
Q1’25 Financial Results Webcast & Call May 14th 2025
Slide 2: Safe harbor statement
Safe harbor statement - This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan," anticipate,” “estimate,” “intend,” “should,” “believe,” “would,” “could,” “potential,” “outlook,” “
Slide 3: Strategic Pillars and Key Imperatives for 2025
Strategic Pillars and Key Imperatives for 2025 Drive utilization through Support & sustain the adoption of VIA software installed base of routine across routine OGM users & OGM & VIA software users facilitate menu expansion Improve profitability and Build support needed for scalability with lower co
Slide 4: First Quarter 2025 Update
First Quarter 2025 Update 4
Slide 5: First Quarter 2025 Results
• Q1 Revenues: $6.5M First Quarter 2025 Results (-26% vs. Q1’24; -11% vs Q1’24 core revenues) • Q1 flowcells (FCs) sold: 6,994 (-15% vs. Q1’24); excluding FCs sold to new customers, FCs purchased were +1% in Q1’25 vs Q1’24) OGM Install Base Revenue ($M) • GAAP Gross margin of 46% (+14% vs. Q1’24); n
Slide 6: Revenue analysis shows steady contribution from our routine users
Revenue analysis shows steady contribution from our routine users who generate the vast majority of consumables revenue Revenue Flowcells (FCs) sold $8.8 million Q1 ‘24 -$1.4 million (discontinued clinical services) -$1.6 million (instrument sales) 8,249 FCs sold -2,388 FCs sold (in connection with
Slide 7: Publications
We believe the growth in publications and clinical research genomes published are important for building support for widespread use of OGM 95 Publications in Q1 2025, which is 2nd highest Over ~9,100 published human clinical research genomes. single quarter for publications (vs 99 in Q1 2024) and a
Slide 8: Key publications underscore utility of OGM & adoption by KOLs
Key publications underscore utility of OGM & adoption by KOLs in cytogenomics for heme malignancies and constitutional genetic disorders Heme malignancies – Multiple Myeloma Constitutional genetic disorders – Repeat Expansion Disorders • Novel OGM workflow for multiple • OGM accurately sized long re
Slide 9: Important steps to reduce cash burn and extend runway
Important steps to reduce cash burn and extend runway Gross Margin Trend: 2023-2025 by Quarter Gross Margin Improvement 50% Non-GAAP Gross Margin Non-GAAP Core GM ✓ Gross Margin for the core business (non- 45% Core Revenues GAAP) has improved from 22% in Q1 2023 to 40% 46% in Q1 2025 35% 30% Cumulat
Slide 10: Financial Overview
Financial Overview bionano 10
Slide 11: Bionano is focused on driving existing customer sites and key target geographies
Bionano is focused on driving existing customer sites that are expanding capacity and in key target geographies Streamlined Business Focus 2025 Guidance • Support & sustain the installed FY’25 Total Revenue Guidance: base of routine OGM & VIA software users $26 – $30M • Drive utilization through ado
Slide 12: Questions & Answers
Questions & Answers bionano 12
Slide 13: Thank you.
= Thank you.